Efficacy and Safety of Telmisartan Compared With Losartan

NCT06431477 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2024-05-28

No results posted yet for this study

Summary

A study to evaluate the efficacy and safety of telmisartan compared with losartan in patients with diabetic nephropathy and hypertension

Conditions

Interventions

DRUG

telmisartan

QD, PO

DRUG

Losartan

QD, PO

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • BeomSeok Kim, M.D, Ph.D · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-19
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06431477 on ClinicalTrials.gov